

APPLICATION FORM FOR RESEARCH PROJECT PROPOSAL REVIEW

FOR OFFICE USE ONLY: PROPOSAL ID NO: _____

Review type New Revised Received on

D	D	M	M	Y	Y	Y	Y
---	---	---	---	---	---	---	---

Review class Exempted Expedited Full Review by IHREC IAEEC

Review group IEC Ad-hoc members Review on

D	D	M	M	Y	Y	Y	Y
---	---	---	---	---	---	---	---

Signature of Member Secretary

TO BE FILLED IN CAPITAL LETTERS BY PRINCIPAL INVESTIGATOR

PROPOSAL TITLE: _____

Investigators	Name, Designation & Qualifications	Address / Tel & Fax Nos. Email ID	Signature
Principal Investigator			
Co-Investigators			

Curriculum Vitae of Investigators:

SPONSOR INFORMATION

1. Indian a. Government Central State Institutional

b. Private

2. International Government Private UN agencies

3. Industry National Multinational

Contact address of the Sponsor:

Total Budget:

PROJECT DETAILS:

1. **Type of Study** : Epidemiological Basic Sciences Animal Studies Clinical
 Behavioral Single Centre Multicentric

2. **Status of Review** : New Revised

3. **Clinical Trials** : Drug/Vaccines/Device/Herbal remedies/Others

i. Does the study involve use of:

Drug Devices Vaccines
 ISM / ASM* Any other NA

* ISM – Indian Systems of Medicine / ASM – Alternate Systems of Medicine

ii. Is it approved and marketed in:

India UK & Europe USA
 Other Countries, specify _____

iii. Does it involve a change in use, dosage, route of administration? Yes No

If Yes, whether DCGI's / any other regulatory authority's permission is obtained? Yes No

If Yes, Date of Permission

D	D	M	M	Y	Y	Y	Y
---	---	---	---	---	---	---	---

iv. Is it an Investigational New Drug Yes No

If Yes, Investigational New Drug No:

a. Investigator's Brochure submitted Yes No

b. In vitro studies data Yes No

c. Preclinical studies done Yes No

d. Clinical Study is Phase I Phase II Phase III Phase IV

e. Are you aware if this study / similar study is being done elsewhere? Yes No

If Yes, attach details.

4. Brief description of the proposal:

5. Subject selection :

i. Number of subjects (sample size) : _____

ii. Duration of the study : _____

iii. Will study subjects from both sexes be recruited Yes No

iv. Inclusion / Exclusion criteria given Yes No

v. Type of subjects Volunteers Patients

vi. Vulnerable subjects Yes No

Pregnant women Children Elderly Fetus

Illiterate Handicapped Terminally ill Seriously ill

Mentally challenged Economically & Socially backward Any other

vii. Special group subjects

Captives Institutionalized Employees Students

Nurses Armed forces Dependant staff Any other

6. Privacy and Confidentiality:

i. Study involves Direct identifiers Indirect identifiers / coded Complete anonymity / delinked

ii. Confidential handling of data by staff Yes No

7. Use of Biological / Hazardous materials

i. Use of fetal tissue or abortus Yes No

ii. Use of organs or body fluids Yes No

iii. Use of recombinant / gene therapy Yes No

If Yes, has Department of Biotechnology (DBT) approval for rDNA products been obtained? Yes No

iv. Use of pre-existing / stored / left over samples Yes No

v. Collection for banking / future research Yes No

vi. Use of ionizing radiation / radio-isotopes Yes No

If Yes, has Bhaba Atomic Research Centre (BARC) approval for Radioactive Isotopes been obtained? Yes No

vii. Use of infectious / bio-hazardous specimens Yes No

viii. Proper disposal of materials Yes No

ix. Will any sample collected from patients be sent to abroad? Yes No

If Yes, justify with details of collaborators.

a. Is the proposal being submitted for clearance from Health Ministry's Screening Committee (HMSC) for International collaboration? Yes No

b. Sample will be sent abroad because:

Facility not available in India Facility in India inaccessible Facility available, but not being accessed. If so reasons

8. Consent Written * Oral Audio-visual

i. If written consent is obtained, tick the included elements listed below.

Understandable language Benefits Contact information

Statement that study involves research Compensation for participation Statement that consent is voluntary

Sponsor of the study Compensation for study related injury Right to withdraw

Purposes and procedures Alternatives to participation Consent for future use of biological material

Risks & Discomforts Confidentiality of records Benefits if any on future commercialization. Eg. Genetic basis for drug devpt

* If written consent is not obtained, then give reasons.

ii. Who will obtain consent PI / Co-PI Research staff Nurse / Counselor Others

9. Will any advertising be done for recruitment of subjects? (Posters, flyers, brochures, websites – if so kindly attach a copy) Yes No

10. Risks & Benefits:

- i. Is the risk reasonable compared to the anticipated benefits to subjects / community / country Yes No

- ii. Is there physical / social / psychological risk / discomfort Yes No
If Yes, Minimal or no risk More than Minimum risk High risk

- iii. Is there a benefit to Subject Society
 Direct Indirect

11. Data Monitoring

- i. Is there a data & safety monitoring committee / board (DSMB)? Yes No

- ii. Is there a plan for reporting of adverse events? Yes No

- iii. If Yes reporting is done to Sponsor Ethics Committee DSMB

- iv. Is there a plan for interim analysis of data? Yes No

- v. Are there plans for storage and maintenance of all trial databases? Yes No
If Yes, for how long.

12. Is there compensation for participation?

Yes No

If Yes, Monetary In kind Specify amount & type: _____

13. Is there compensation for injury?

Yes No

If Yes,
 By Sponsor By Investigator By Insurance Company By any other

14. Do you have conflict of interest (financial / non-financial)

Yes No

If Yes, specify: _____

15. Checklist for attached documents:

Brief description of proposal

Copy of clinical trial protocol and/or questionnaire

Curriculum Vitae of Investigators

Institutional Ethics Committee Clearance

Patient information sheet

Institutional Animal Ethics Committee Clearance

Consent form

CPCSEA clearance, if any.

Investigator's brochure for recruiting subjects

HMSC / DCGI / DBT / BARC clearance if obtained

Copy of advertisements / Information brochures

Place:

Signature & Designation of PI

Date:

Please Note: This IEC application form should be forwarded by the Head of the Department to which the Principal Investigator is affiliated.

Signature of the Head

Department of _____

Date: